ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print
Health Technology

Takeda Pharmaceutical Co., Ltd.

Business Summary

Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. It operates through the following segments: Prescription Drug, Consumer Healthcare, and Other. The Prescription Drugs segment includes the manufacture and sale of pharmaceutical products. The Consumer Healthcare segment includes the manufacture and sale of OTC drugs and quasi-drugs. The Other segment includes manufacture and sale of reagents, clinical diagnostics, and chemical products. The company was founded by Takeda Chobei on June 12, 1781 and is headquartered in Osaka, Japan.

Financial Highlights

Mar 2023 JPYUSD
Gross Profit2,240.96B16,536.34M
Operating income610,329M4,503.69M
Income before tax383,720M2,831.51M
Net income317,017M2,339.30M
Diluted EPS201.931.49
Dividends Per Share1801.32
Total Assets13,957.75B104,874.52M
Total liabilities7,603.08B57,127.35M
Total equity6,354.12B47,743.04M
Operating cash flow877,217M6,473.09M
Currency in JPYCurrency in USD

Historical Data

 Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Revenue 2,097.22B 3,291.18B 3,197.81B 3,569.00B 4,027.47B
Gross Profit 1,275.55B 1,789.37B 1,798.37B 2,043.63B 2,240.96B
Operating income 218,686M 302,612M 447,610M 610,496M 610,329M
Income before tax 127,612M -60,754M 366,159M 317,938M 383,720M
Net income 135,192M 44,241M 376,005M 230,059M 317,017M
EBITDA 466,377M 886,261M 1,007.28B 1,193.64B 1,274.72B
Diluted EPS 139.82 28.24 238.95 145.86 201.93
Dividends Per Share 180 180 180 180 180
Total Assets 13,792.77B 12,821.09B 12,912.29B 13,178.01B 13,957.75B
Total liabilities 8,606.78B 8,093.60B 7,735.11B 7,494.49B 7,603.08B
Total equity 5,181.98B 4,723.48B 5,173.03B 5,683.01B 6,354.12B
Operating cash flow 302,609M 555,410M 905,073M 1,021.21B 877,217M
 Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Revenue 18,911.85M 30,270.54M 30,151.70M 31,760.44M 29,719.25M
Gross Profit 11,502.42M 16,457.72M 16,956.61M 18,186.20M 16,536.34M
Operating income 1,972.01M 2,783.25M 4,220.44M 5,432.77M 4,503.69M
Income before tax 1,150.74M -558.78M 3,452.46M 2,829.31M 2,831.51M
Net income 1,219.10M 406.90M 3,545.29M 2,047.28M 2,339.30M
EBITDA 4,205.58M 8,151.34M 9,497.50M 10,622.21M 9,406.38M
Diluted EPS 1.26 0.25 2.25 1.29 1.49
Dividends Per Share 1.62 1.65 1.69 1.60 1.32
Total Assets 124,612.85M 118,763.31M 116,853.33M 108,572.75M 104,874.52M
Total liabilities 77,759.25M 74,972.05M 70,001.05M 61,746.62M 57,127.35M
Total equity 46,817.41M 43,754.18M 46,814.81M 46,821.99M 47,743.04M
Operating cash flow 2,728.79M 5,108.35M 8,533.80M 9,087.77M 6,473.09M

Valuation Measures

Mar 2023
Operating margin15.15%
Profit margin7.87%

Key executives

  • President, CEO & Representative Director: Christophe Weber
  • Chief Financial Officer & Director: Constantine Saroukos
  • Director, President-Research & Development: Andrew S. Plump
  • Chief Medical & Scientific Officer: Michael E. Mendelsohn
  • Chief Accounting Officer & Corporate Controller: Norimasa Takeda


  • Nomura Asset Management Co., Ltd. (4.2%)
  • Sumitomo Mitsui Trust Asset Management Co., Ltd. (3.8%)
  • The Vanguard Group, Inc. (2.5%)
  • Nikko Asset Management Co., Ltd. (2.0%)
  • Daiwa Asset Management Co. Ltd. (1.9%)
  • BlackRock Fund Advisors (1.8%)
  • Nippon Life Insurance Co. (1.8%)
  • Capital Research & Management Co. (Global Investors) (1.6%)
  • Norges Bank Investment Management (1.5%)
  • Capital International Ltd. (1.3%)

Contact Details

Related Companies

  • Takeda Pharmaceutical Co Ltd /Asker Pharma Manufacturing Ops/
  • Nimbus Lakshmi, Inc.
  • Takeda Digital Ventures
  • Takeda Pharmaceutical Employee Long Term Incentive Plan
  • Takeda Dunboyne Biologics Ltd.
  • Plasmaspendedienst GmbH
  • Takeda Belgium NV
  • Takeda Pharmaceutical Co. Ltd. /Non Core Assets/
  • Adaptate Biotherapeutics Ltd.
  • Takeda Re Insurance AG
  • Plasmapunkt Favoriten GmbH
  • Takeda Malaysia Sdn. Bhd.
  • Takeda Pharmaceutical Co. Ltd. /Latam Bus/
  • Takeda Oranienburg Real Estate GmbH & Co. KG
  • Pvp Biologics, Inc.
  • Maverick Therapeutics, Inc.
  • Gammadelta Therapeutics Ltd.
  • Takeda Pharmaceutical Director Incentive Plan
  • Takeda Pharmaceutical Employee Incentive Plan
  • Oy Leiras Takeda Pharmaceuticals AB
  • Takeda Architectural Design Consulting (Shanghai) Co. Ltd.
  • Takeda Pharma AB
  • Takeda Development Center Americas, Inc.
  • Takeda Ukraine LLC
  • Takeda Pharmaceuticals Taiwan Ltd.
  • Takeda SRL
  • Takeda Hellas SA
  • Takeda Christiaens SCA/CVA
  • Takeda Belgium SCA/CVA
  • Takeda Vaccines Pte Ltd.


  • AstraZeneca PLC
  • Grifols, S.A. Class A
  • Green Cross Corporation
  • Amgen Inc.
  • CSL Limited
  • Novo Nordisk A/S Class B
  • Amicus Therapeutics, Inc.
  • Pharming Group NV
  • Protalix Biotherapeutics, Inc.
  • ADMA Biologics, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Johnson & Johnson
  • Sanofi
  • Mochida Pharmaceutical Co., Ltd.
  • AbbVie, Inc.
  • Bristol-Myers Squibb Company
  • Organon & Co.
  • Merck & Co., Inc.
  • Bayer AG
  • Roche Holding Ltd Dividend Right Cert.
  • Karyopharm Therapeutics, Inc.
  • Swedish Orphan Biovitrum AB
  • UCB S.A.
  • Merck KGaA
  • JCR Pharmaceuticals Co., Ltd.
  • Supernus Pharmaceuticals, Inc.
  • Oncopeptides AB
  • BioCryst Pharmaceuticals, Inc.
  • ISU Abxis Co., Ltd.
Last Updated on 26 May, 2023

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more